Abstract
To evaluate the cost-effectiveness of nivolumab versus taxane-based chemotherapy (TbC) for previously treated advanced esophageal squamous cell carcinoma (aESCC) patients from a United States (US) payer perspective using data with minimum 36-months follow-up from the ATTRACTION-3 trial.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
